111 related articles for article (PubMed ID: 36198130)
21. Patterns of recurrence in women with advanced and recurrent epithelial ovarian cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Chambers LM; Yao M; Morton M; Gruner M; Chichura A; Horowitz M; Costales AB; Rose PG; Michener CM; Debernardo R
Gynecol Oncol; 2021 May; 161(2):389-395. PubMed ID: 33551202
[TBL] [Abstract][Full Text] [Related]
22. Primary cytoreductive surgery and adjuvant hormonal monotherapy in women with advanced low-grade serous ovarian carcinoma: Reducing overtreatment without compromising survival?
Fader AN; Bergstrom J; Jernigan A; Tanner EJ; Roche KL; Stone RL; Levinson KL; Ricci S; Wethingon S; Wang TL; Shih IM; Yang B; Zhang G; Armstrong DK; Gaillard S; Michener C; DeBernardo R; Rose PG
Gynecol Oncol; 2017 Oct; 147(1):85-91. PubMed ID: 28768570
[TBL] [Abstract][Full Text] [Related]
23. Interval debulking surgery is not worth the wait: a National Cancer Database study comparing primary cytoreductive surgery versus neoadjuvant chemotherapy.
Lyons YA; Reyes HD; McDonald ME; Newtson A; Devor E; Bender DP; Goodheart MJ; Gonzalez Bosquet J
Int J Gynecol Cancer; 2020 Jun; 30(6):845-852. PubMed ID: 32341114
[TBL] [Abstract][Full Text] [Related]
24. Total parietal peritonectomy performed during interval cytoreductive surgery for advanced epithelial serous ovarian cancer results in a low incidence of platinum resistant recurrence- results of a prospective multi-centre study.
Bhatt A; Sinukumar S; Parikh L; Mehta S; Shaikh S; Jumle N; Kammar P
Eur J Surg Oncol; 2021 Aug; 47(8):2150-2157. PubMed ID: 33875284
[TBL] [Abstract][Full Text] [Related]
25. Transitory Stoma at the Time of Complete Cytoreductive Surgery Affects Survival for Patients with Advanced-stage Ovarian Cancer.
Canlorbe G; Touboul C; Chargari C; Bentivegna E; Maulard A; Pautier P; Genestie C; Morice P; Gouy S
Anticancer Res; 2018 Mar; 38(3):1517-1523. PubMed ID: 29491080
[TBL] [Abstract][Full Text] [Related]
26. Cytoreductive Surgery (CRS) Combined With Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Platinum-Sensitive Recurrence Epithelial Ovarian Cancer With HRR Mutation: A Phase III Randomized Clinical Trial.
Qi Y; Zhang Y; Shi Y; Yao S; Dai M; Cai H
Technol Cancer Res Treat; 2022; 21():15330338221104565. PubMed ID: 35929135
[No Abstract] [Full Text] [Related]
27. Pattern of recurrence after interval cytoreductive surgery and HIPEC following neoadjuvant chemotherapy in primary advanced stage IIIC/IVA epithelial ovarian cancer.
Sinukumar S; Damodaran D; Ray M; Mehta S; Paul L; Bhatt A
Eur J Surg Oncol; 2021 Jun; 47(6):1427-1433. PubMed ID: 33509612
[TBL] [Abstract][Full Text] [Related]
28. Primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) for FIGO stage III epithelial ovarian cancer: OVHIPEC-2, a phase III randomized clinical trial.
Koole S; van Stein R; Sikorska K; Barton D; Perrin L; Brennan D; Zivanovic O; Mosgaard BJ; Fagotti A; Colombo PE; Sonke G; Driel WJV;
Int J Gynecol Cancer; 2020 Jun; 30(6):888-892. PubMed ID: 32205449
[TBL] [Abstract][Full Text] [Related]
29. Survival outcomes after delayed cytoreduction surgery following neoadjuvant chemotherapy in advanced epithelial ovarian cancer.
Yao SE; Tripcony L; Sanday K; Robertson J; Perrin L; Chetty N; Land R; Garrett A; Obermair A; Nascimento M; Tang A; Jagasia N; Singh P; Nicklin J
Int J Gynecol Cancer; 2020 Dec; 30(12):1935-1942. PubMed ID: 33122245
[TBL] [Abstract][Full Text] [Related]
30. Study of upfront surgery versus neoadjuvant chemotherapy followed by interval debulking surgery for patients with stage IIIC and IV ovarian cancer, SGOG SUNNY (SOC-2) trial concept.
Jiang R; Zhu J; Kim JW; Liu J; Kato K; Kim HS; Zhang Y; Zhang P; Zhu T; Aoki D; Yu A; Chen X; Wang X; Zhu D; Zhang W; Jia H; Shi T; Gao W; Yin S; Feng Y; Xiang L; Okamoto A; Zang R
J Gynecol Oncol; 2020 Sep; 31(5):e86. PubMed ID: 32808504
[TBL] [Abstract][Full Text] [Related]
31. Outcomes for Elderly Ovarian Cancer Patients Treated with Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC).
Zambrano-Vera K; Sardi A; Lopez-Ramirez F; Sittig M; Munoz-Zuluaga C; Nieroda C; Gushchin V; Diaz-Montes T
Ann Surg Oncol; 2021 Aug; 28(8):4655-4666. PubMed ID: 33393042
[TBL] [Abstract][Full Text] [Related]
32. A novel treatment protocol with 6 cycles of neoadjuvant chemotherapy followed by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in stage III primary ovarian cancer.
Marrelli D; Petrioli R; Cassetti D; D'Ignazio A; Marsili S; Mazzei MA; Lazzi S; Roviello F
Surg Oncol; 2021 Jun; 37():101523. PubMed ID: 33545658
[TBL] [Abstract][Full Text] [Related]
33. Prognostic factors for maximally or optimally cytoreduced stage III nonserous epithelial ovarian carcinoma treated with carboplatin/paclitaxel chemotherapy.
Cuylan ZF; Meydanli MM; Sari ME; Akbayir O; Celik H; Dede M; Sahin H; Gungorduk K; Kuscu E; Ozgul N; Gungor T; Ayhan A
J Obstet Gynaecol Res; 2018 Jul; 44(7):1284-1293. PubMed ID: 29727055
[TBL] [Abstract][Full Text] [Related]
34. The American Society of Peritoneal Surface Malignancies Multi-Institution evaluation of 1,051 advanced ovarian cancer patients undergoing cytoreductive surgery and HIPEC: An introduction of the peritoneal surface disease severity score.
Foster JM; Sleightholm R; Smith L; Ceelen W; Deraco M; Yildirim Y; Levine E; Muñoz-Casares C; Glehen O; Patel A; Esquivel J
J Surg Oncol; 2016 Dec; 114(7):779-784. PubMed ID: 27792292
[TBL] [Abstract][Full Text] [Related]
35. FDG-PET/CT to predict optimal primary cytoreductive surgery in patients with advanced ovarian cancer: preliminary results.
Alessi A; Martinelli F; Padovano B; Serafini G; Lorusso D; Lorenzoni A; Ditto A; Lecce F; Mira M; Donfrancesco C; Raspagliesi F; Crippa F
Tumori; 2016; 102(1):103-7. PubMed ID: 26350201
[TBL] [Abstract][Full Text] [Related]
36. Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III study.
Spiliotis J; Halkia E; Lianos E; Kalantzi N; Grivas A; Efstathiou E; Giassas S
Ann Surg Oncol; 2015 May; 22(5):1570-5. PubMed ID: 25391263
[TBL] [Abstract][Full Text] [Related]
37. Impact of bevacizumab and secondary cytoreductive surgery on survival outcomes in platinum-sensitive relapsed ovarian clear cell carcinoma: A multicenter study in Korea.
Kim SI; Kim JH; Noh JJ; Kim SH; Kim TE; Kim K; Park JY; Lim MC; Lee JW; Kim JW
Gynecol Oncol; 2022 Sep; 166(3):444-452. PubMed ID: 35863991
[TBL] [Abstract][Full Text] [Related]
38. Cytoreduction (Peritonectomy Procedures) Combined with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Advanced Ovarian Cancer: Retrospective Italian Multicenter Observational Study of 511 Cases.
Di Giorgio A; De Iaco P; De Simone M; Garofalo A; Scambia G; Pinna AD; Verdecchia GM; Ansaloni L; Macrì A; Cappellini P; Ceriani V; Giorda G; Biacchi D; Vaira M; Valle M; Sammartino P
Ann Surg Oncol; 2017 Apr; 24(4):914-922. PubMed ID: 27896512
[TBL] [Abstract][Full Text] [Related]
39. Concordance of laparoscopic and laparotomic peritoneal cancer index using a two-step surgical protocol to select patients for cytoreductive surgery in advanced ovarian cancer.
Angeles MA; Migliorelli F; Del M; Martínez-Gómez C; Daix M; Bétrian S; Gabiache E; Balagué G; Leclerc S; Mery E; Gladieff L; Ferron G; Martinez A
Arch Gynecol Obstet; 2021 May; 303(5):1295-1304. PubMed ID: 33389113
[TBL] [Abstract][Full Text] [Related]
40. The role of cytoreductive surgery and HIPEC in epithelial ovarian cancer.
Halkia E; Spiliotis J
J BUON; 2015 May; 20 Suppl 1():S12-28. PubMed ID: 26051328
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]